Supplementary Figure 6 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Biagio Ricciuti; Arielle Elkrief; Joao V. Alessi; Xinan Wang; Yvonne Li; Hersh Gupta; Daniel M. Muldoon; Arrien A. Bertram; Federica Pecci; Giuseppe Lamberti; Alessandro Di Federico; Adriana Barrichello; Victor R. Vaz; Malini Gandhi; Elinton Lee; Geoffrey I. Shapiro; Hyesun Park; Mizuki Nishino; James Lindsay; Kristen D. Felt; Bijaya Sharma; Andrew D. Cherniack; Scott J. Rodig; Daniel R. Gomez; Narek Shaverdian; Mehrdad Rakaee; Chaitanya Bandlamudi; Marc Ladanyi; Pasi A. Jänne; Adam J. Schoenfeld; Lynette M. Sholl; Mark M. Awad; Michael L. Cheng

doi:10.1158/1078-0432.27031159

Abstract

Supplementary Figure 6. (A) Tumor mutational burden and (B) PD-L1 tumor proportion score distributions according to ATM protein expression by IHC (lost versus intact).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ricciuti et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522e0a https://doi.org/10.1158/1078-0432.27031159

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 6 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Abstract

Discussion

Cite This Study

Supplementary Figure 6 from Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer

Abstract

Discussion

Cite This Study

Keep reading

Keep reading